Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2026 | $15.00 | Outperform | Wedbush |
| 11/4/2024 | $15.00 | Outperform | Leerink Partners |
| 9/5/2024 | $5.00 | Neutral | H.C. Wainwright |
| 5/3/2024 | $26.00 | Overweight | Piper Sandler |
| 10/10/2023 | $10.00 | Buy | Ladenburg Thalmann |
| 8/25/2023 | $17.00 | Outperform | Oppenheimer |
| 6/22/2023 | $20.00 | Buy | Guggenheim |
| 6/14/2023 | $14.00 | Buy | Chardan Capital Markets |
4 - Zura Bio Ltd (0001855644) (Issuer)
3 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027 Cash and cash equivalents of $109.4 million as of December 31, 2025 Completed an underwritten public offering in February 2026 for gross proceeds of approximately $144 million; post‑financing cash and cash equivalents expected to support planned operations through at least the end of 2028 Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical‑stage biotechnology company developing novel and differentiated medi
Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. The poster, titled "TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of
Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Leerink Global Healthcare Conference Location: Miami, FL Fireside chat: Tuesday, March 10, 2026, at 2:20 p.m. ET Investor meetings: Management will meet with investors Jefferies Biotech on the Beach Summit Location: Miami, FL Date: Wednesday, March 11, 2026 Investor meetings: Management will meet with
10-K - Zura Bio Ltd (0001855644) (Filer)
8-K - Zura Bio Ltd (0001855644) (Filer)
8-K - Zura Bio Ltd (0001855644) (Filer)
Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00
Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00
H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a
Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701021645/en/Eric Hyllengren Mr. Badial joined Zura Bio in March 2023, at the time of its business combination with
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G - Zura Bio Ltd (0001855644) (Subject)
Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria
Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress